1. Home
  2. CDIO vs FBGL Comparison

CDIO vs FBGL Comparison

Compare CDIO & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDIO
  • FBGL
  • Stock Information
  • Founded
  • CDIO 2017
  • FBGL 1996
  • Country
  • CDIO United States
  • FBGL Singapore
  • Employees
  • CDIO N/A
  • FBGL N/A
  • Industry
  • CDIO Biotechnology: Commercial Physical & Biological Resarch
  • FBGL Miscellaneous manufacturing industries
  • Sector
  • CDIO Health Care
  • FBGL Consumer Discretionary
  • Exchange
  • CDIO Nasdaq
  • FBGL Nasdaq
  • Market Cap
  • CDIO 20.2M
  • FBGL 23.6M
  • IPO Year
  • CDIO N/A
  • FBGL 2025
  • Fundamental
  • Price
  • CDIO $0.50
  • FBGL $1.02
  • Analyst Decision
  • CDIO Buy
  • FBGL
  • Analyst Count
  • CDIO 1
  • FBGL 0
  • Target Price
  • CDIO $2.00
  • FBGL N/A
  • AVG Volume (30 Days)
  • CDIO 2.5M
  • FBGL 1.9M
  • Earning Date
  • CDIO 03-31-2025
  • FBGL 01-01-0001
  • Dividend Yield
  • CDIO N/A
  • FBGL N/A
  • EPS Growth
  • CDIO N/A
  • FBGL N/A
  • EPS
  • CDIO N/A
  • FBGL 0.04
  • Revenue
  • CDIO $35,688.00
  • FBGL $15,607,369.00
  • Revenue This Year
  • CDIO $228.74
  • FBGL N/A
  • Revenue Next Year
  • CDIO $854.55
  • FBGL N/A
  • P/E Ratio
  • CDIO N/A
  • FBGL $27.55
  • Revenue Growth
  • CDIO 180.90
  • FBGL 25.78
  • 52 Week Low
  • CDIO $0.19
  • FBGL $0.87
  • 52 Week High
  • CDIO $1.86
  • FBGL $5.45
  • Technical
  • Relative Strength Index (RSI)
  • CDIO 45.05
  • FBGL N/A
  • Support Level
  • CDIO $0.47
  • FBGL N/A
  • Resistance Level
  • CDIO $0.69
  • FBGL N/A
  • Average True Range (ATR)
  • CDIO 0.08
  • FBGL 0.00
  • MACD
  • CDIO 0.01
  • FBGL 0.00
  • Stochastic Oscillator
  • CDIO 33.88
  • FBGL 0.00

About CDIO Cardio Diagnostics Holdings Inc. Common stock

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Share on Social Networks: